What is Chonluten researched for?

Chonluten is described as a synthetic EDG tripeptide in the Khavinson bioregulator group. The source frames it as being studied for respiratory tissue, lung function, bronchial support, and age-associated respiratory decline, while also noting that rigorous randomized human evidence is absent.

How is Chonluten proposed to work?

The proposed model is that Chonluten can enter cells and influence gene-expression patterns relevant to respiratory epithelium. The source treats this as a Khavinson-style gene-regulation hypothesis supported mainly by cell, animal, and institute-linked observations rather than as an established human drug mechanism.

Is Chonluten FDA approved?

No. The supplied source states that Chonluten is not FDA approved and is not EMA approved. It also reports supplement approval in Russia, which should not be interpreted as FDA approval.

What side effects are reported for Chonluten?

The source reports that Chonluten is generally described as well tolerated, but it also emphasizes limited safety data outside Russia and lack of FDA approval. These statements do not establish a complete adverse-event profile.

What dose is reported for Chonluten?

The source reports community and research-context dosing around 10-20 mg daily, with once- or twice-daily use and oral capsule or sublingual administration. These are source-reported research and community patterns, not treatment instructions.

Bioregulators Preclinical - animal studies only

Chonluten

Also known as: Glu-Asp-Gly, EDG

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Synthetic EDG tripeptide researched as a respiratory bioregulator

Status

Preclinical

Evidence level: animal studies

Typical dose

10–20mg

Oral capsules or sublingual

Researched for

Respiratory health, lung function, bronchial support

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

Synthetic tripeptide also referred to as Glu-Asp-Gly or EDG.
Positioned in the Khavinson bioregulator family and researched for respiratory tissue, lung function, and bronchial support.
Source reports no FDA or EMA approval and describes the evidence base as or uncontrolled observational work.
Reported dose patterns are 10-20 mg daily, once or twice daily, using oral capsules or sublingual administration.
No registered randomized controlled human trials were reported in the supplied evidence.

How it's thought to work

Chonluten is presented under the Khavinson bioregulator framework, where short peptides are proposed to enter cells and influence nuclear gene-expression activity. For Chonluten specifically, the source links the hypothesis to respiratory epithelial tissue and genes related to stress response, antioxidant activity, and inflammation. The same evidence cautions that this remains a proposed mechanism, with uncertainty about whether free EDG reaches human nuclei at relevant concentrations or binds specific DNA regions in a clinically meaningful way.

What the research shows

Where the research stands

The supplied source connects Chonluten, the EDG tripeptide, to Khavinson-group work on bronchopulmonary tissue. It reports discussion of oral EDG in chronic bronchitis with an asthmatic component and mentions related work pairing EDG with Bronchogen in chronic obstructive pulmonary disease contexts. The evidence base is described as concentrated in one research network, with uncontrolled clinical observations, limited independent replication, no registered randomized controlled trials, and mechanistic claims relying on cell-culture or animal findings rather than confirmed human outcomes.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Preclinical research; reported supplement approval in Russia; not FDA or EMA approved Not FDA approved

Typical dosing

CommunityCommunity dataset

10–20 mg

daily

10 mgfull range seen20 mg

Community-reported use frames Chonluten as a lung-tissue bioregulator for respiratory support. This is not a medical dosing recommendation.

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

10-20 mg daily

Animal study doses may not translate directly to humans.

Duration: 10-30 day cycles
Administration: Oral capsules or sublingual

Timing & administration

Best time to take

Morning on an empty stomach

Once or twice daily

Food recommendation

Take on an empty stomach

Why this timing?

The source says this class is commonly timed away from food to support absorption; this is a reported timing rationale rather than a proven clinical requirement.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well tolerated in the source report
Limited safety data outside Russia
Not FDA approved

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

H-Glu-Asp-Gly-OH (EDG)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Chonluten

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Chonluten

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions